Closed to Accrual: ME.15

The ME.15 (MelMarT-II) phase III randomized control trial investigating 1cm vs 2cm wide excision margins for primary cutaneous melanoma has closed to accrual after reaching the accrual target of 3000 patients enrolled. This study is investigating the use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient and improve quality of lift.

“Thank you to all our participating sites for their outstanding efforts in recruiting patients and helping us achieve our target. Your dedication and commitment to the success of the MelMarT-II trial are deeply appreciated, and we couldn’t have reached this milestone without your support. We also extend a special thank you to all the patients who are currently participating, and those who have participated in the trial. Your contribution is invaluable” -  Study Chair Prof Michael Henderson

For more information >